Nuvectis Pharma, Inc. (NVCT)
Automate Your Wheel Strategy on NVCT
With Tiblio's Option Bot, you can configure your own wheel strategy including NVCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVCT
- Rev/Share 0.0
- Book/Share 1.051
- PB 8.9535
- Debt/Equity 0.0
- CurrentRatio 3.2791
- ROIC -1.0031
- MktCap 196607901.0
- FreeCF/Share -0.605
- PFCF -16.2984
- PE -9.3057
- Debt/Assets 0.0
- DivYield 0
- ROE -1.4883
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVCT | Maxim Group | -- | Buy | -- | $17 | April 2, 2025 |
| Initiation | NVCT | Laidlaw | -- | Buy | -- | $19 | March 17, 2025 |
News
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 108.8% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $NVCT #Pharma--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safe.
Read More
About Nuvectis Pharma, Inc. (NVCT)
- IPO Date 2022-02-04
- Website https://www.nuvectis.com
- Industry Biotechnology
- CEO Mr. Ron Bentsur M.B.A.
- Employees 13